CA2646429A1 - 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders - Google Patents

Info

Publication number

CA2646429A1

CA2646429A1 CA002646429A CA2646429A CA2646429A1 CA 2646429 A1 CA2646429 A1 CA 2646429A1 CA 002646429 A CA002646429 A CA 002646429A CA 2646429 A CA2646429 A CA 2646429A CA 2646429 A1 CA2646429 A1 CA 2646429A1

Authority

CA

Canada

Prior art keywords

purin

amine

ethyl

pyridin

phenyl

Prior art date

2006-03-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims abstract description 28
• 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims abstract description 27
• 238000011282 treatment Methods 0.000 claims abstract description 24
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 21
• 208000008589 Obesity Diseases 0.000 claims abstract description 20
• 235000020824 obesity Nutrition 0.000 claims abstract description 20
• 230000002265 prevention Effects 0.000 claims abstract description 20
• 208000030159 metabolic disease Diseases 0.000 claims abstract description 15
• 238000000034 method Methods 0.000 claims description 304
• 150000001875 compounds Chemical class 0.000 claims description 107
• -1 cyano, nitro, amino Chemical group 0.000 claims description 41
• 125000000217 alkyl group Chemical group 0.000 claims description 40
• 229910052757 nitrogen Inorganic materials 0.000 claims description 24
• 125000003118 aryl group Chemical group 0.000 claims description 21
• 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 20
• 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 20
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 17
• 125000001072 heteroaryl group Chemical group 0.000 claims description 17
• 239000001257 hydrogen Substances 0.000 claims description 17
• 125000003545 alkoxy group Chemical group 0.000 claims description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
• 229910052736 halogen Inorganic materials 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 14
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 14
• 150000002367 halogens Chemical class 0.000 claims description 13
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 11
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 10
• 125000004103 aminoalkyl group Chemical group 0.000 claims description 10
• 230000002401 inhibitory effect Effects 0.000 claims description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
• 125000004442 acylamino group Chemical group 0.000 claims description 7
• 125000004945 acylaminoalkyl group Chemical group 0.000 claims description 7
• 125000003282 alkyl amino group Chemical group 0.000 claims description 7
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
• 150000002431 hydrogen Chemical class 0.000 claims description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
• PVUIOAOUQPLJTC-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 PVUIOAOUQPLJTC-UHFFFAOYSA-N 0.000 claims description 6
• 206010006895 Cachexia Diseases 0.000 claims description 6
• 125000002252 acyl group Chemical group 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 6
• 201000001883 cholelithiasis Diseases 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
• 208000001130 gallstones Diseases 0.000 claims description 6
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
• 201000002859 sleep apnea Diseases 0.000 claims description 6
• 125000001424 substituent group Chemical group 0.000 claims description 6
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 5
• 208000030814 Eating disease Diseases 0.000 claims description 5
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
• 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 5
• 235000014632 disordered eating Nutrition 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 229910052731 fluorine Inorganic materials 0.000 claims description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
• 208000032839 leukemia Diseases 0.000 claims description 5
• 201000008482 osteoarthritis Diseases 0.000 claims description 5
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 4
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
• 239000011737 fluorine Substances 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• QZTXFEFHGSSLLO-UHFFFAOYSA-N n-(4-fluorophenyl)-8-pyridin-4-yl-7h-purin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(N2)C=3C=CN=CC=3)C2=N1 QZTXFEFHGSSLLO-UHFFFAOYSA-N 0.000 claims description 4
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 4
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
• WZJMKKBGBBEOHS-UHFFFAOYSA-N 2,2,2-trifluoro-n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(=O)C(F)(F)F)C=C1 WZJMKKBGBBEOHS-UHFFFAOYSA-N 0.000 claims description 3
• HYGPEUXRWYLOIN-UHFFFAOYSA-N 3-[2-(3-methoxyanilino)-8-pyrimidin-4-ylpurin-9-yl]propanenitrile Chemical compound COC1=CC=CC(NC=2N=C3N(CCC#N)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 HYGPEUXRWYLOIN-UHFFFAOYSA-N 0.000 claims description 3
• GSSIKTIGYYEYMO-UHFFFAOYSA-N 3-[8-(2-aminopyrimidin-4-yl)-2-(3-methoxyanilino)purin-9-yl]propanenitrile Chemical compound COC1=CC=CC(NC=2N=C3N(CCC#N)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 GSSIKTIGYYEYMO-UHFFFAOYSA-N 0.000 claims description 3
• NHBSGCNHKNJDPS-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 NHBSGCNHKNJDPS-UHFFFAOYSA-N 0.000 claims description 3
• ZEBHVVDCUCLCHN-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 ZEBHVVDCUCLCHN-UHFFFAOYSA-N 0.000 claims description 3
• QUMUQLOQNDKVFM-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(4-fluoro-3-methoxyphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 QUMUQLOQNDKVFM-UHFFFAOYSA-N 0.000 claims description 3
• XQNSTUNYRQGUTD-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 XQNSTUNYRQGUTD-UHFFFAOYSA-N 0.000 claims description 3
• ONQZRROTKQAVST-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-n-(3,4-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 ONQZRROTKQAVST-UHFFFAOYSA-N 0.000 claims description 3
• NAZLPTWWZCLEGV-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4C=C(N)N=CC=4)=NC3=CN=2)=C1 NAZLPTWWZCLEGV-UHFFFAOYSA-N 0.000 claims description 3
• XYQZJJVYRGHMIH-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-n-(4-fluorophenyl)-9-methylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 XYQZJJVYRGHMIH-UHFFFAOYSA-N 0.000 claims description 3
• BJXSTXQFDAMJBO-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 BJXSTXQFDAMJBO-UHFFFAOYSA-N 0.000 claims description 3
• NZBVUKPKBZXNEM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-fluorophenyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(F)C=CC=4)=NC=C3N=2)C2CC2)=N1 NZBVUKPKBZXNEM-UHFFFAOYSA-N 0.000 claims description 3
• LBUYYVMDIUYIQM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-methylphenyl)purin-2-amine Chemical compound CC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 LBUYYVMDIUYIQM-UHFFFAOYSA-N 0.000 claims description 3
• YIBMLVFQUNJWTN-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(4-fluorophenyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C2CC2)=N1 YIBMLVFQUNJWTN-UHFFFAOYSA-N 0.000 claims description 3
• ZWVBYQWMUYSQFE-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=N1 ZWVBYQWMUYSQFE-UHFFFAOYSA-N 0.000 claims description 3
• RTJAUHQFEDUFFL-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC=C1C RTJAUHQFEDUFFL-UHFFFAOYSA-N 0.000 claims description 3
• XBMKEEBOFTZPDJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluoro-4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C(F)=C1 XBMKEEBOFTZPDJ-UHFFFAOYSA-N 0.000 claims description 3
• XQBFABALBUOMFZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1 XQBFABALBUOMFZ-UHFFFAOYSA-N 0.000 claims description 3
• XPWBIWZPFJXZAP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-ethylphenyl)purin-2-amine Chemical compound C1=CC(CC)=CC=C1NC1=NC=C(N=C(C=2N=C(N)N=CC=2)N2CC)C2=N1 XPWBIWZPFJXZAP-UHFFFAOYSA-N 0.000 claims description 3
• ZXHUFUJXDSAJCQ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1C ZXHUFUJXDSAJCQ-UHFFFAOYSA-N 0.000 claims description 3
• KDYPIICQVSPKMD-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(C)=C1 KDYPIICQVSPKMD-UHFFFAOYSA-N 0.000 claims description 3
• YKXGRIRISAGLQD-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YKXGRIRISAGLQD-UHFFFAOYSA-N 0.000 claims description 3
• DVPGOFKHIYJKOF-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(5,6,7,8-tetrahydronaphthalen-1-yl)purin-2-amine Chemical compound N=1C2=CN=C(NC=3C=4CCCCC=4C=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 DVPGOFKHIYJKOF-UHFFFAOYSA-N 0.000 claims description 3
• ZIKBLUKPDFVYJQ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(5-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC=C1C ZIKBLUKPDFVYJQ-UHFFFAOYSA-N 0.000 claims description 3
• CJINNKPHGFAJBZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1F CJINNKPHGFAJBZ-UHFFFAOYSA-N 0.000 claims description 3
• JROADSMIBPKINP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dihydro-1h-inden-4-yl)-9-ethylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=4CCCC=4C=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 JROADSMIBPKINP-UHFFFAOYSA-N 0.000 claims description 3
• UAOBQSOZRAWNRN-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dihydro-1h-inden-5-yl)-9-ethylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4CCCC4=CC=3)N=C2N(CC)C=1C1=CC=NC(N)=N1 UAOBQSOZRAWNRN-UHFFFAOYSA-N 0.000 claims description 3
• GZHQOWSFWOKEST-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,3-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1C GZHQOWSFWOKEST-UHFFFAOYSA-N 0.000 claims description 3
• LRPGHDNBVLBTRM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,4-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1F LRPGHDNBVLBTRM-UHFFFAOYSA-N 0.000 claims description 3
• ZXCKOEZXNLZFED-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,4-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1C ZXCKOEZXNLZFED-UHFFFAOYSA-N 0.000 claims description 3
• ZSCUKTFACZMWCO-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,5-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC=C1F ZSCUKTFACZMWCO-UHFFFAOYSA-N 0.000 claims description 3
• YMROIJUEVYGXLM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,5-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(C)=CC=C1C YMROIJUEVYGXLM-UHFFFAOYSA-N 0.000 claims description 3
• QSUJBCZKUIYDAI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2,6-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=C(F)C=CC=C1F QSUJBCZKUIYDAI-UHFFFAOYSA-N 0.000 claims description 3
• WAVDPBGCYDVJMF-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chloro-4-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC(F)=CC=4)Cl)=NC=C3N=2)C2CC2)=N1 WAVDPBGCYDVJMF-UHFFFAOYSA-N 0.000 claims description 3
• MJSFVHQRTFALHV-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chloro-5-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC=C(F)C=4)Cl)=NC=C3N=2)C2CC2)=N1 MJSFVHQRTFALHV-UHFFFAOYSA-N 0.000 claims description 3
• UNYFPFJIOAAHDI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(2-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC=C1Cl UNYFPFJIOAAHDI-UHFFFAOYSA-N 0.000 claims description 3
• LKLPSMRQPSLPDC-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,4-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 LKLPSMRQPSLPDC-UHFFFAOYSA-N 0.000 claims description 3
• DDXSNLQGUWIDOP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,4-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C(C)=C1 DDXSNLQGUWIDOP-UHFFFAOYSA-N 0.000 claims description 3
• PJQSHEDWLPFTEM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,5-difluorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(F)=CC(F)=C1 PJQSHEDWLPFTEM-UHFFFAOYSA-N 0.000 claims description 3
• NUTDEBPDDVELNJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3,5-dimethylphenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC(C)=CC(C)=C1 NUTDEBPDDVELNJ-UHFFFAOYSA-N 0.000 claims description 3
• KCWHWBDLUBKRON-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chloro-2-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=C(Cl)C=CC=4)F)=NC=C3N=2)C2CC2)=N1 KCWHWBDLUBKRON-UHFFFAOYSA-N 0.000 claims description 3
• WXPIEKTXAWQUCR-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chloro-4-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C(F)=CC=4)=NC=C3N=2)C2CC2)=N1 WXPIEKTXAWQUCR-UHFFFAOYSA-N 0.000 claims description 3
• BYAYUIDASASDNM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chlorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C=CC=4)=NC=C3N=2)C2CC2)=N1 BYAYUIDASASDNM-UHFFFAOYSA-N 0.000 claims description 3
• OPGGSXVCGUHKTG-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(Cl)=C1 OPGGSXVCGUHKTG-UHFFFAOYSA-N 0.000 claims description 3
• LLKWJSVYFODKGI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 LLKWJSVYFODKGI-UHFFFAOYSA-N 0.000 claims description 3
• JZRNPHRSVLUEDZ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-chloro-2-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC(Cl)=CC=4)F)=NC=C3N=2)C2CC2)=N1 JZRNPHRSVLUEDZ-UHFFFAOYSA-N 0.000 claims description 3
• BUWCGYCENTWUQM-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-chlorophenyl)-9-ethylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(Cl)C=C1 BUWCGYCENTWUQM-UHFFFAOYSA-N 0.000 claims description 3
• KNDQGRSIMXKUSP-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-fluorophenyl)-9-methylpurin-2-amine Chemical compound N1=C2N(C)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 KNDQGRSIMXKUSP-UHFFFAOYSA-N 0.000 claims description 3
• GISBRRIKYIRFBV-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound C1=NC(Cl)=CC(C=2N(C3=NC(NCCC=4SC=CC=4)=NC=C3N=2)C2CC2)=C1 GISBRRIKYIRFBV-UHFFFAOYSA-N 0.000 claims description 3
• PQTLIVNTYOKNQG-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound C1=NC(Cl)=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=C1 PQTLIVNTYOKNQG-UHFFFAOYSA-N 0.000 claims description 3
• WVKZPZQQIQZLRA-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 WVKZPZQQIQZLRA-UHFFFAOYSA-N 0.000 claims description 3
• QMYWKEOMADJKGX-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-n-(3-methoxyphenyl)-9-propan-2-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 QMYWKEOMADJKGX-UHFFFAOYSA-N 0.000 claims description 3
• WYQFVKIKCKBYHG-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=NC(N)=CC=4)=NC3=CN=2)=C1 WYQFVKIKCKBYHG-UHFFFAOYSA-N 0.000 claims description 3
• YNDWIOYGPZEHHJ-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-9-ethyl-n-(4-fluorophenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3C=NC(N)=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YNDWIOYGPZEHHJ-UHFFFAOYSA-N 0.000 claims description 3
• PAPJNYYKUHRNAN-UHFFFAOYSA-N 8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)-7h-purin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)NC2=NC=1NCCC1=CC=CS1 PAPJNYYKUHRNAN-UHFFFAOYSA-N 0.000 claims description 3
• VKQRYONUADIMLP-UHFFFAOYSA-N 9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]-n-(3-methylphenyl)purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(C)C=CC=4)=NC=C3N=2)C2CC2)=N1 VKQRYONUADIMLP-UHFFFAOYSA-N 0.000 claims description 3
• OSBKRHDCCLRWLM-UHFFFAOYSA-N 9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]-n-phenylpurin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=N1 OSBKRHDCCLRWLM-UHFFFAOYSA-N 0.000 claims description 3
• XVNMGGMAZPTHIV-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-[3-(trifluoromethoxy)phenyl]purin-2-amine Chemical compound FC(F)(F)OC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 XVNMGGMAZPTHIV-UHFFFAOYSA-N 0.000 claims description 3
• NGGDOPRXNBBLKF-UHFFFAOYSA-N 9-cyclopropyl-8-pyrimidin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3N=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NGGDOPRXNBBLKF-UHFFFAOYSA-N 0.000 claims description 3
• PYWHJJIUMDLXKQ-UHFFFAOYSA-N 9-cyclopropyl-n-(2-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound FC1=CC=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 PYWHJJIUMDLXKQ-UHFFFAOYSA-N 0.000 claims description 3
• MNZMPTJPAKSVHS-UHFFFAOYSA-N 9-cyclopropyl-n-(3-ethylphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(NC)N=CC=4)=NC3=CN=2)=C1 MNZMPTJPAKSVHS-UHFFFAOYSA-N 0.000 claims description 3
• ZZQRWDRUNISRQQ-UHFFFAOYSA-N 9-cyclopropyl-n-(3-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(F)C=CC=4)=NC=C3N=2)C2CC2)=N1 ZZQRWDRUNISRQQ-UHFFFAOYSA-N 0.000 claims description 3
• JBXJDBLTKOEXSR-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-pyrimidin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 JBXJDBLTKOEXSR-UHFFFAOYSA-N 0.000 claims description 3
• XZGGGDHKYSGMNC-UHFFFAOYSA-N 9-cyclopropyl-n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C2CC2)=N1 XZGGGDHKYSGMNC-UHFFFAOYSA-N 0.000 claims description 3
• NTEZSWHZWMLNNS-UHFFFAOYSA-N 9-cyclopropyl-n-[3-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C=1C=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=CC=1OCCN1CCOCC1 NTEZSWHZWMLNNS-UHFFFAOYSA-N 0.000 claims description 3
• DMHMLTMJTDGBPZ-UHFFFAOYSA-N 9-cyclopropyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 DMHMLTMJTDGBPZ-UHFFFAOYSA-N 0.000 claims description 3
• CTAJMNAZMJJEDD-UHFFFAOYSA-N 9-cyclopropyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 CTAJMNAZMJJEDD-UHFFFAOYSA-N 0.000 claims description 3
• KSFYQXBAGPACQL-UHFFFAOYSA-N 9-cyclopropyl-n-phenyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC=3C=CC=CC=3)=NC=C2N=C1C1=CC=NC=C1 KSFYQXBAGPACQL-UHFFFAOYSA-N 0.000 claims description 3
• LIIWSMMSGDTMAE-UHFFFAOYSA-N 9-ethyl-n-(3-ethylphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4N=C(NC)N=CC=4)=NC3=CN=2)=C1 LIIWSMMSGDTMAE-UHFFFAOYSA-N 0.000 claims description 3
• DSRXMYCCMKHUAE-UHFFFAOYSA-N 9-ethyl-n-(4-fluoro-3-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 DSRXMYCCMKHUAE-UHFFFAOYSA-N 0.000 claims description 3
• RWUGJXUJUMDRNM-UHFFFAOYSA-N 9-ethyl-n-[3-(2-methoxyethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(OCCOC)=C1 RWUGJXUJUMDRNM-UHFFFAOYSA-N 0.000 claims description 3
• FQJRBITYKOCDKP-UHFFFAOYSA-N 9-ethyl-n-[3-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1OCCN1CCOCC1 FQJRBITYKOCDKP-UHFFFAOYSA-N 0.000 claims description 3
• SVFRGHJASFOKEE-UHFFFAOYSA-N 9-ethyl-n-[3-(2-piperidin-1-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1OCCN1CCCCC1 SVFRGHJASFOKEE-UHFFFAOYSA-N 0.000 claims description 3
• PWQVITAVWFKFIW-UHFFFAOYSA-N 9-ethyl-n-[3-(ethylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound CCNCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 PWQVITAVWFKFIW-UHFFFAOYSA-N 0.000 claims description 3
• HHHOWXQLRMMJDE-UHFFFAOYSA-N 9-ethyl-n-[3-[(propan-2-ylamino)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CNC(C)C)=C1 HHHOWXQLRMMJDE-UHFFFAOYSA-N 0.000 claims description 3
• ZVULPPVKKPIYNY-UHFFFAOYSA-N 9-ethyl-n-[3-[2-(ethylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound CCNCCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 ZVULPPVKKPIYNY-UHFFFAOYSA-N 0.000 claims description 3
• MTFACQXGLMPJIB-UHFFFAOYSA-N 9-ethyl-n-[3-[2-(propan-2-ylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CCNC(C)C)=C1 MTFACQXGLMPJIB-UHFFFAOYSA-N 0.000 claims description 3
• RMIGYMSGAIENSJ-UHFFFAOYSA-N 9-ethyl-n-[4-(2-methoxyethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(OCCOC)C=C1 RMIGYMSGAIENSJ-UHFFFAOYSA-N 0.000 claims description 3
• HVMQAXFYSZQCJI-UHFFFAOYSA-N 9-ethyl-n-[4-(2-morpholin-4-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1OCCN1CCOCC1 HVMQAXFYSZQCJI-UHFFFAOYSA-N 0.000 claims description 3
• BGZQEYTYZMHHBG-UHFFFAOYSA-N 9-ethyl-n-[4-(2-piperidin-1-ylethoxy)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1OCCN1CCCCC1 BGZQEYTYZMHHBG-UHFFFAOYSA-N 0.000 claims description 3
• AGQPZCNJZAXRBB-UHFFFAOYSA-N 9-ethyl-n-[4-(ethylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNCC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC)C2=N1 AGQPZCNJZAXRBB-UHFFFAOYSA-N 0.000 claims description 3
• VRVGCRZYHMPPEW-UHFFFAOYSA-N 9-ethyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC)C=C1 VRVGCRZYHMPPEW-UHFFFAOYSA-N 0.000 claims description 3
• WTSPFSNVEDVUKQ-UHFFFAOYSA-N 9-ethyl-n-[4-[(propan-2-ylamino)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(C)C)C=C1 WTSPFSNVEDVUKQ-UHFFFAOYSA-N 0.000 claims description 3
• AZFBBBZAAXJYDR-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(ethylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNCC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC)C2=N1 AZFBBBZAAXJYDR-UHFFFAOYSA-N 0.000 claims description 3
• LNBJHYNELVITJQ-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCNC)C=C1 LNBJHYNELVITJQ-UHFFFAOYSA-N 0.000 claims description 3
• UFEPWKZHQMKCAS-UHFFFAOYSA-N 9-ethyl-n-[4-[2-(propan-2-ylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCNC(C)C)C=C1 UFEPWKZHQMKCAS-UHFFFAOYSA-N 0.000 claims description 3
• ZFHPAFXEJGOZDW-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[3-(2-pyrrolidin-1-ylethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCCC1 ZFHPAFXEJGOZDW-UHFFFAOYSA-N 0.000 claims description 3
• YOUJWGSMRBRFQB-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[3-(pyrrolidin-1-ylmethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCCC1 YOUJWGSMRBRFQB-UHFFFAOYSA-N 0.000 claims description 3
• LUCZZVHZJFEMCD-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[4-(2-pyrrolidin-1-ylethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCCC1 LUCZZVHZJFEMCD-UHFFFAOYSA-N 0.000 claims description 3
• DKHVQTGWOGQLCK-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-[4-(pyrrolidin-1-ylmethyl)phenyl]purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCCC1 DKHVQTGWOGQLCK-UHFFFAOYSA-N 0.000 claims description 3
• PRMFGMRJTDHQLR-UHFFFAOYSA-N 9-methyl-n-[3-(2-morpholin-4-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCOCC1 PRMFGMRJTDHQLR-UHFFFAOYSA-N 0.000 claims description 3
• LAKWSPNLJOWAPV-UHFFFAOYSA-N 9-methyl-n-[3-(2-piperazin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCNCC1 LAKWSPNLJOWAPV-UHFFFAOYSA-N 0.000 claims description 3
• GOOFAHMXVRLDHU-UHFFFAOYSA-N 9-methyl-n-[3-(2-piperidin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCN1CCCCC1 GOOFAHMXVRLDHU-UHFFFAOYSA-N 0.000 claims description 3
• AJELQPXEYGUQPF-UHFFFAOYSA-N 9-methyl-n-[3-(morpholin-4-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCOCC1 AJELQPXEYGUQPF-UHFFFAOYSA-N 0.000 claims description 3
• BPEWWPDJYWGJER-UHFFFAOYSA-N 9-methyl-n-[3-(piperazin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCNCC1 BPEWWPDJYWGJER-UHFFFAOYSA-N 0.000 claims description 3
• HCSLILLYWYXDJV-UHFFFAOYSA-N 9-methyl-n-[3-(piperidin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CN1CCCCC1 HCSLILLYWYXDJV-UHFFFAOYSA-N 0.000 claims description 3
• UIVQKYBCYIRMFQ-UHFFFAOYSA-N 9-methyl-n-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 UIVQKYBCYIRMFQ-UHFFFAOYSA-N 0.000 claims description 3
• WYCKFLGURNNCKO-UHFFFAOYSA-N 9-methyl-n-[3-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CCC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 WYCKFLGURNNCKO-UHFFFAOYSA-N 0.000 claims description 3
• WICOBPMYLCUPKO-UHFFFAOYSA-N 9-methyl-n-[4-(2-morpholin-4-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCOCC1 WICOBPMYLCUPKO-UHFFFAOYSA-N 0.000 claims description 3
• OMLDCPBOYYSBRO-UHFFFAOYSA-N 9-methyl-n-[4-(2-piperazin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCNCC1 OMLDCPBOYYSBRO-UHFFFAOYSA-N 0.000 claims description 3
• VDGIEODIGVRUHU-UHFFFAOYSA-N 9-methyl-n-[4-(2-piperidin-1-ylethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCN1CCCCC1 VDGIEODIGVRUHU-UHFFFAOYSA-N 0.000 claims description 3
• ULXPBRKJHKFUAU-UHFFFAOYSA-N 9-methyl-n-[4-(methylaminomethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ULXPBRKJHKFUAU-UHFFFAOYSA-N 0.000 claims description 3
• QPQLPPDWPUQPRA-UHFFFAOYSA-N 9-methyl-n-[4-(morpholin-4-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 QPQLPPDWPUQPRA-UHFFFAOYSA-N 0.000 claims description 3
• ULGLNVPCXHERLJ-UHFFFAOYSA-N 9-methyl-n-[4-(piperazin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCNCC1 ULGLNVPCXHERLJ-UHFFFAOYSA-N 0.000 claims description 3
• RAAGZBFPKOIRAF-UHFFFAOYSA-N 9-methyl-n-[4-(piperidin-1-ylmethyl)phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CN1CCCCC1 RAAGZBFPKOIRAF-UHFFFAOYSA-N 0.000 claims description 3
• NTIPFZGDPFRSAA-UHFFFAOYSA-N 9-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 NTIPFZGDPFRSAA-UHFFFAOYSA-N 0.000 claims description 3
• OLIBBAODESAITO-UHFFFAOYSA-N 9-methyl-n-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1CN(C)CCN1CCC(C=C1)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 OLIBBAODESAITO-UHFFFAOYSA-N 0.000 claims description 3
• XSUYJNHRKYXUTP-UHFFFAOYSA-N 9-methyl-n-[4-[2-(methylamino)ethyl]phenyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCNC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 XSUYJNHRKYXUTP-UHFFFAOYSA-N 0.000 claims description 3
• UJQUJFKXQNLARQ-UHFFFAOYSA-N [4-[2-(4-fluoroanilino)-9-methylpurin-8-yl]pyridin-2-yl]methanol Chemical compound N1=C2N(C)C(C=3C=C(CO)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 UJQUJFKXQNLARQ-UHFFFAOYSA-N 0.000 claims description 3
• 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 3
• 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
• 125000004414 alkyl thio group Chemical group 0.000 claims description 3
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 3
• FWHYCPPXCXIERA-UHFFFAOYSA-N ethyl 4-[2-(4-fluoroanilino)-9-methylpurin-8-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OCC)=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C)=C1 FWHYCPPXCXIERA-UHFFFAOYSA-N 0.000 claims description 3
• 125000001188 haloalkyl group Chemical group 0.000 claims description 3
• HQEJLLJOQVQIRW-UHFFFAOYSA-N n-(3,4-difluorophenyl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 HQEJLLJOQVQIRW-UHFFFAOYSA-N 0.000 claims description 3
• QZFRMJLDOBBTNQ-UHFFFAOYSA-N n-(3-chlorophenyl)-9-cyclopropyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(Cl)C=CC=4)=NC=C3N=2)C2CC2)=N1 QZFRMJLDOBBTNQ-UHFFFAOYSA-N 0.000 claims description 3
• IRPQXSQAPKVCNJ-UHFFFAOYSA-N n-(3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]-9-propan-2-ylpurin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(OC)C=CC=4)=NC=C3N=2)C(C)C)=N1 IRPQXSQAPKVCNJ-UHFFFAOYSA-N 0.000 claims description 3
• DNZFCTAPXIOPCB-UHFFFAOYSA-N n-(3-methoxyphenyl)-9-propan-2-yl-8-pyrimidin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C(C)C)C(C=4N=CN=CC=4)=NC3=CN=2)=C1 DNZFCTAPXIOPCB-UHFFFAOYSA-N 0.000 claims description 3
• AMHAUXXDQNPBJG-UHFFFAOYSA-N n-(4-fluorophenyl)-8-pyridin-4-yl-9-(2,2,2-trifluoroethyl)purin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2CC(F)(F)F)C2=N1 AMHAUXXDQNPBJG-UHFFFAOYSA-N 0.000 claims description 3
• YIGZCAPHNFVCDA-UHFFFAOYSA-N n-(4-fluorophenyl)-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 YIGZCAPHNFVCDA-UHFFFAOYSA-N 0.000 claims description 3
• FVZYADGFRJUBRR-UHFFFAOYSA-N n-(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)-1,3-benzothiazol-6-amine Chemical compound C1CC1N1C2=NC(NC=3C=C4SC=NC4=CC=3)=NC=C2N=C1C1=CC=NC=C1 FVZYADGFRJUBRR-UHFFFAOYSA-N 0.000 claims description 3
• MUGWGRLZTQAQSZ-UHFFFAOYSA-N n-[2-[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]-n-methylacetamide Chemical compound C1=CC(CCN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 MUGWGRLZTQAQSZ-UHFFFAOYSA-N 0.000 claims description 3
• SXCZYSHPDFNYFF-UHFFFAOYSA-N n-[2-[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 SXCZYSHPDFNYFF-UHFFFAOYSA-N 0.000 claims description 3
• PZSKMDBKCUQLSQ-UHFFFAOYSA-N n-[2-[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]-n-methylacetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN(C)C(C)=O)C=C1 PZSKMDBKCUQLSQ-UHFFFAOYSA-N 0.000 claims description 3
• ILIFXEKKMSMPGQ-UHFFFAOYSA-N n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenoxy]ethyl]acetamide Chemical compound C1=CC(OCCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ILIFXEKKMSMPGQ-UHFFFAOYSA-N 0.000 claims description 3
• MNBAMJCWNUBYCM-UHFFFAOYSA-N n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 MNBAMJCWNUBYCM-UHFFFAOYSA-N 0.000 claims description 3
• XZQIWHORMUJUAO-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN)=C1 XZQIWHORMUJUAO-UHFFFAOYSA-N 0.000 claims description 3
• YMOIYAVQZHMYKO-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN)=C1 YMOIYAVQZHMYKO-UHFFFAOYSA-N 0.000 claims description 3
• NEBVWSHXGASCPA-UHFFFAOYSA-N n-[3-[(cyclopentylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CNC1CCCC1 NEBVWSHXGASCPA-UHFFFAOYSA-N 0.000 claims description 3
• HFJYWXYHBBNIPE-UHFFFAOYSA-N n-[3-[(cyclopropylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CNC1CC1 HFJYWXYHBBNIPE-UHFFFAOYSA-N 0.000 claims description 3
• PMYVIYLCXFHEFG-UHFFFAOYSA-N n-[3-[(dimethylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CN(C)C)=C1 PMYVIYLCXFHEFG-UHFFFAOYSA-N 0.000 claims description 3
• YSPRFZGDWDJEIV-UHFFFAOYSA-N n-[3-[2-(cyclopentylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCNC1CCCC1 YSPRFZGDWDJEIV-UHFFFAOYSA-N 0.000 claims description 3
• VLFPMHOMHHVGFL-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethoxy]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(OCCN(C)C)=C1 VLFPMHOMHHVGFL-UHFFFAOYSA-N 0.000 claims description 3
• XLMZJSDZMREDIT-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CCN(C)C)=C1 XLMZJSDZMREDIT-UHFFFAOYSA-N 0.000 claims description 3
• ARKUPPIJRKHOQJ-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CCN)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 ARKUPPIJRKHOQJ-UHFFFAOYSA-N 0.000 claims description 3
• UBKCUPRGGJDJDT-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN)C=C1 UBKCUPRGGJDJDT-UHFFFAOYSA-N 0.000 claims description 3
• BNBWRDTUJSXOCU-UHFFFAOYSA-N n-[4-(2-methoxyethoxy)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 BNBWRDTUJSXOCU-UHFFFAOYSA-N 0.000 claims description 3
• ZJRUCIFBIBWCBX-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(CN)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 ZJRUCIFBIBWCBX-UHFFFAOYSA-N 0.000 claims description 3
• RYWLVHKOIQOBEP-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN)C=C1 RYWLVHKOIQOBEP-UHFFFAOYSA-N 0.000 claims description 3
• MXTFGJHPLWKYSA-UHFFFAOYSA-N n-[4-[(cyclopentylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CNC1CCCC1 MXTFGJHPLWKYSA-UHFFFAOYSA-N 0.000 claims description 3
• HHNWSGKIGKJFDE-UHFFFAOYSA-N n-[4-[(cyclopropylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CNC1CC1 HHNWSGKIGKJFDE-UHFFFAOYSA-N 0.000 claims description 3
• ULGHTHURLGXNFB-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN(C)C)C=C1 ULGHTHURLGXNFB-UHFFFAOYSA-N 0.000 claims description 3
• JMUKEJDKNVEFCR-UHFFFAOYSA-N n-[4-[2-(cyclopentylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCNC1CCCC1 JMUKEJDKNVEFCR-UHFFFAOYSA-N 0.000 claims description 3
• WFRIHVMTHVXYFQ-UHFFFAOYSA-N n-[4-[2-(cyclopropylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=C1)=CC=C1CCNC1CC1 WFRIHVMTHVXYFQ-UHFFFAOYSA-N 0.000 claims description 3
• TZZAQIBVLVSJRQ-UHFFFAOYSA-N n-[4-[2-(dimethylamino)ethoxy]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(OCCN(C)C)C=C1 TZZAQIBVLVSJRQ-UHFFFAOYSA-N 0.000 claims description 3
• QRDDBBUWGNAOTD-UHFFFAOYSA-N n-[4-[2-(dimethylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN(C)C)C=C1 QRDDBBUWGNAOTD-UHFFFAOYSA-N 0.000 claims description 3
• COJTYKYQOPTTII-UHFFFAOYSA-N n-[[3-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 COJTYKYQOPTTII-UHFFFAOYSA-N 0.000 claims description 3
• CDZNBVIUVDVHNN-UHFFFAOYSA-N n-[[3-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=CC(CNC(C)=O)=C1 CDZNBVIUVDVHNN-UHFFFAOYSA-N 0.000 claims description 3
• JJVBHRSWNYATBJ-UHFFFAOYSA-N n-[[3-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC=2N=C3N(C)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 JJVBHRSWNYATBJ-UHFFFAOYSA-N 0.000 claims description 3
• FOBBQUHCVZKXKB-UHFFFAOYSA-N n-[[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]-n-methylacetamide Chemical compound C1=CC(CN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 FOBBQUHCVZKXKB-UHFFFAOYSA-N 0.000 claims description 3
• WEWBMCRSGXJWDU-UHFFFAOYSA-N n-[[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]-n-methylacetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN(C)C(C)=O)C=C1 WEWBMCRSGXJWDU-UHFFFAOYSA-N 0.000 claims description 3
• RIIQCCYYKOYGOR-UHFFFAOYSA-N n-[[4-[(9-ethyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CNC(C)=O)C=C1 RIIQCCYYKOYGOR-UHFFFAOYSA-N 0.000 claims description 3
• ZQXYZELNAKHPJZ-UHFFFAOYSA-N n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound C1=CC(CNC(=O)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 ZQXYZELNAKHPJZ-UHFFFAOYSA-N 0.000 claims description 3
• SXVGDYQGWQGDIK-UHFFFAOYSA-N n-cyclopentyl-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC3CCCC3)=NC=C2N=C1C1=CC=NC=C1 SXVGDYQGWQGDIK-UHFFFAOYSA-N 0.000 claims description 3
• KTNMDJYVQXCDKZ-UHFFFAOYSA-N n-methyl-n-[2-[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]acetamide Chemical compound C1=CC(CCN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 KTNMDJYVQXCDKZ-UHFFFAOYSA-N 0.000 claims description 3
• VAWSNENNHSSRON-UHFFFAOYSA-N n-methyl-n-[[4-[(9-methyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]acetamide Chemical compound C1=CC(CN(C)C(C)=O)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 VAWSNENNHSSRON-UHFFFAOYSA-N 0.000 claims description 3
• 125000001544 thienyl group Chemical group 0.000 claims description 3
• 125000003396 thiol group Chemical class [H]S* 0.000 claims description 3
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
• OJAYHSXTIMOYHA-UHFFFAOYSA-N 3-ethyl-n-[4-(methylaminomethyl)phenyl]-2-pyridin-4-ylimidazo[4,5-b]pyridin-5-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CC=C1NC1=CC=C(CNC)C=C1 OJAYHSXTIMOYHA-UHFFFAOYSA-N 0.000 claims description 2
• LKOGQCVPWVTMRE-UHFFFAOYSA-N 8-(2-aminopyridin-4-yl)-9-cyclopropyl-n-phenylpurin-2-amine Chemical compound C1=NC(N)=CC(C=2N(C3=NC(NC=4C=CC=CC=4)=NC=C3N=2)C2CC2)=C1 LKOGQCVPWVTMRE-UHFFFAOYSA-N 0.000 claims description 2
• LSNIYGFKFNDXFJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NCCC=4SC=CC=4)=NC=C3N=2)C2CC2)=N1 LSNIYGFKFNDXFJ-UHFFFAOYSA-N 0.000 claims description 2
• MAIRAYHHNMOQSU-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 MAIRAYHHNMOQSU-UHFFFAOYSA-N 0.000 claims description 2
• OYRYADSSHGWCAC-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC=C1NC1=NC=C(N=C(C=2N=C(N)N=CC=2)N2CC)C2=N1 OYRYADSSHGWCAC-UHFFFAOYSA-N 0.000 claims description 2
• GHWLXBMSIJWFNY-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(2-fluoro-4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1F GHWLXBMSIJWFNY-UHFFFAOYSA-N 0.000 claims description 2
• KQPCWOZUTPDLAJ-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-ethylphenyl)purin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 KQPCWOZUTPDLAJ-UHFFFAOYSA-N 0.000 claims description 2
• ACQIYHOCKIGJAV-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-fluoro-2-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1C ACQIYHOCKIGJAV-UHFFFAOYSA-N 0.000 claims description 2
• GPLOINKNIDSWSL-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1 GPLOINKNIDSWSL-UHFFFAOYSA-N 0.000 claims description 2
• PIZQISPKSKBVSA-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-fluoro-3-methoxyphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 PIZQISPKSKBVSA-UHFFFAOYSA-N 0.000 claims description 2
• ZKXXIMSVOLKANW-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-9-ethyl-n-(4-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1NC1=CC=C(C)C=C1 ZKXXIMSVOLKANW-UHFFFAOYSA-N 0.000 claims description 2
• IISZHWCDEYMYAT-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(4-fluorophenyl)-9-(2,2,2-trifluoroethyl)purin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)CC(F)(F)F)=N1 IISZHWCDEYMYAT-UHFFFAOYSA-N 0.000 claims description 2
• FLUDWWGAKZXMQI-UHFFFAOYSA-N 8-(2-aminopyrimidin-4-yl)-n-(5-chloro-2-fluorophenyl)-9-cyclopropylpurin-2-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C(=CC=C(Cl)C=4)F)=NC=C3N=2)C2CC2)=N1 FLUDWWGAKZXMQI-UHFFFAOYSA-N 0.000 claims description 2
• CDWLGPFXJKITOC-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-9-cyclopropyl-n-(3-methoxyphenyl)purin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=C(Cl)N=CC=4)=NC3=CN=2)=C1 CDWLGPFXJKITOC-UHFFFAOYSA-N 0.000 claims description 2
• NRJVUCQSLBLQCU-UHFFFAOYSA-N 9-cyclopropyl-8-(1,3-thiazol-2-yl)-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3SC=CN=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NRJVUCQSLBLQCU-UHFFFAOYSA-N 0.000 claims description 2
• APENBSBUJLGQKP-UHFFFAOYSA-N 9-cyclopropyl-8-(1-methylpyrrol-2-yl)-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound CN1C=CC=C1C(N(C1=N2)C3CC3)=NC1=CN=C2NCCC1=CC=CS1 APENBSBUJLGQKP-UHFFFAOYSA-N 0.000 claims description 2
• NDMUMHCYGMAQRN-UHFFFAOYSA-N 9-cyclopropyl-8-(1H-pyrrol-2-yl)-N-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3NC=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 NDMUMHCYGMAQRN-UHFFFAOYSA-N 0.000 claims description 2
• GNFVOIJLWIRBEI-UHFFFAOYSA-N 9-cyclopropyl-8-(3-methylimidazol-4-yl)-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound CN1C=NC=C1C(N(C1=N2)C3CC3)=NC1=CN=C2NCCC1=CC=CS1 GNFVOIJLWIRBEI-UHFFFAOYSA-N 0.000 claims description 2
• DWLPOLXCWATSCO-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-3-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N=1C=C2N=C(C=3C=NC=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CS1 DWLPOLXCWATSCO-UHFFFAOYSA-N 0.000 claims description 2
• CKNKWCNHIYCTIG-UHFFFAOYSA-N 9-cyclopropyl-8-pyridin-4-yl-n-(3,4,5-trimethoxyphenyl)purin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 CKNKWCNHIYCTIG-UHFFFAOYSA-N 0.000 claims description 2
• NPAPKEPLPPFZHX-UHFFFAOYSA-N 9-cyclopropyl-n-(2,4-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NPAPKEPLPPFZHX-UHFFFAOYSA-N 0.000 claims description 2
• PHTKYENBCMCMIK-UHFFFAOYSA-N 9-cyclopropyl-n-(2-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 PHTKYENBCMCMIK-UHFFFAOYSA-N 0.000 claims description 2
• DSVLPARUQPEPGL-UHFFFAOYSA-N 9-cyclopropyl-n-(2-methylpropyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NCC(C)C)=NC=C2N=C1C1=CC=NC=C1 DSVLPARUQPEPGL-UHFFFAOYSA-N 0.000 claims description 2
• MKOLXIBPEPDIJM-UHFFFAOYSA-N 9-cyclopropyl-n-(2-phenylethyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C=C2N=C(C=3C=CN=CC=3)N(C3CC3)C2=NC=1NCCC1=CC=CC=C1 MKOLXIBPEPDIJM-UHFFFAOYSA-N 0.000 claims description 2
• NRUCIRIHQFSKIM-UHFFFAOYSA-N 9-cyclopropyl-n-(3,4-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NRUCIRIHQFSKIM-UHFFFAOYSA-N 0.000 claims description 2
• LDDNXGPEDPDBKZ-UHFFFAOYSA-N 9-cyclopropyl-n-(3,5-dimethoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 LDDNXGPEDPDBKZ-UHFFFAOYSA-N 0.000 claims description 2
• WSQNCRJKXUFRCP-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=C(OC)C=CC=4)=NC=C3N=2)C2CC2)=N1 WSQNCRJKXUFRCP-UHFFFAOYSA-N 0.000 claims description 2
• CDWRRSAITRSBIC-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 CDWRRSAITRSBIC-UHFFFAOYSA-N 0.000 claims description 2
• UDPLWYLPGZGTPB-UHFFFAOYSA-N 9-cyclopropyl-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 UDPLWYLPGZGTPB-UHFFFAOYSA-N 0.000 claims description 2
• BVAAJTBOQVJYAL-UHFFFAOYSA-N 9-cyclopropyl-n-(4-methoxyphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 BVAAJTBOQVJYAL-UHFFFAOYSA-N 0.000 claims description 2
• DPVCTRUNOHZWCK-UHFFFAOYSA-N 9-cyclopropyl-n-[(4-methylphenyl)methyl]-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(C)=CC=C1CNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 DPVCTRUNOHZWCK-UHFFFAOYSA-N 0.000 claims description 2
• NYAGIYGPFIPWSK-UHFFFAOYSA-N 9-cyclopropyl-n-[2-(2-fluorophenyl)ethyl]-8-pyridin-4-ylpurin-2-amine Chemical compound FC1=CC=CC=C1CCNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 NYAGIYGPFIPWSK-UHFFFAOYSA-N 0.000 claims description 2
• FNAQKJULHGQKHE-UHFFFAOYSA-N 9-cyclopropyl-n-[2-(2-methoxyphenyl)ethyl]-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC=C1CCNC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 FNAQKJULHGQKHE-UHFFFAOYSA-N 0.000 claims description 2
• SAUCCPWWVPCEBU-UHFFFAOYSA-N 9-ethyl-8-[2-(methylamino)pyrimidin-4-yl]-n-(3-methylphenyl)purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=CC(C)=C1 SAUCCPWWVPCEBU-UHFFFAOYSA-N 0.000 claims description 2
• GYFMZCFUFXNHJD-UHFFFAOYSA-N 9-ethyl-n-(3-ethylphenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound CCC1=CC=CC(NC=2N=C3N(CC)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 GYFMZCFUFXNHJD-UHFFFAOYSA-N 0.000 claims description 2
• DOTMGRGARVEHMA-UHFFFAOYSA-N 9-ethyl-n-(3-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=CC(F)=C1 DOTMGRGARVEHMA-UHFFFAOYSA-N 0.000 claims description 2
• ZVGCPBYRIQCVMK-UHFFFAOYSA-N 9-ethyl-n-(4-fluoro-3-methoxyphenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(OC)=C1 ZVGCPBYRIQCVMK-UHFFFAOYSA-N 0.000 claims description 2
• HXIKLHCOHQNBDY-UHFFFAOYSA-N 9-ethyl-n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 HXIKLHCOHQNBDY-UHFFFAOYSA-N 0.000 claims description 2
• IEWVLVLAYSCVOY-UHFFFAOYSA-N 9-ethyl-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 IEWVLVLAYSCVOY-UHFFFAOYSA-N 0.000 claims description 2
• HATJPVJOVWDDHI-UHFFFAOYSA-N 9-methyl-8-pyridin-4-yl-n-(2-thiophen-2-ylethyl)purin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NCCC1=CC=CS1 HATJPVJOVWDDHI-UHFFFAOYSA-N 0.000 claims description 2
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
• ZNMNMHHOKYRNQM-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1CC1N1C2=NC(NC=3C=C4OCOC4=CC=3)=NC=C2N=C1C1=CC=NC=C1 ZNMNMHHOKYRNQM-UHFFFAOYSA-N 0.000 claims description 2
• SVOLIXKSJUYSNV-UHFFFAOYSA-N n-(2,2-dimethyl-1,3-benzodioxol-5-yl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4OC(C)(C)OC4=CC=3)N=C2N(CC)C=1C1=CC=NC=C1 SVOLIXKSJUYSNV-UHFFFAOYSA-N 0.000 claims description 2
• NPAVJSROLVUUBX-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N=1C2=CN=C(NC=3C=C4OCCOC4=CC=3)N=C2N(CC)C=1C1=CC=NC=C1 NPAVJSROLVUUBX-UHFFFAOYSA-N 0.000 claims description 2
• FISCLDSEZJEGTR-UHFFFAOYSA-N n-(3,4-difluorophenyl)-9-ethyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(NC)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C(F)=C1 FISCLDSEZJEGTR-UHFFFAOYSA-N 0.000 claims description 2
• UJVDSFLOFDDOOH-UHFFFAOYSA-N n-(4-chlorophenyl)-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 UJVDSFLOFDDOOH-UHFFFAOYSA-N 0.000 claims description 2
• LQSQHRDYXHKTIV-UHFFFAOYSA-N n-(4-fluorophenyl)-8-[2-(methylamino)pyrimidin-4-yl]-9-(2,2,2-trifluoroethyl)purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)CC(F)(F)F)=N1 LQSQHRDYXHKTIV-UHFFFAOYSA-N 0.000 claims description 2
• MJXUUHBPUUOUSI-UHFFFAOYSA-N n-(4-fluorophenyl)-9-methyl-8-[2-(methylamino)pyrimidin-4-yl]purin-2-amine Chemical compound CNC1=NC=CC(C=2N(C3=NC(NC=4C=CC(F)=CC=4)=NC=C3N=2)C)=N1 MJXUUHBPUUOUSI-UHFFFAOYSA-N 0.000 claims description 2
• IRZYBDYWVGMCSY-UHFFFAOYSA-N n-(4-methoxyphenyl)-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C)C2=N1 IRZYBDYWVGMCSY-UHFFFAOYSA-N 0.000 claims description 2
• BVKIHXDYFHWWLF-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-9-cyclopropyl-8-pyridin-4-ylpurin-2-amine Chemical compound NCC1=CC=CC(NC=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 BVKIHXDYFHWWLF-UHFFFAOYSA-N 0.000 claims description 2
• QMWWXCLWMSIYAD-UHFFFAOYSA-N n-[3-[2-(cyclopropylamino)ethyl]phenyl]-9-ethyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(CC)C(C=3C=CN=CC=3)=NC2=CN=C1NC(C=1)=CC=CC=1CCNC1CC1 QMWWXCLWMSIYAD-UHFFFAOYSA-N 0.000 claims description 2
• VCVCXSPOZXMIFE-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CCN)C=C1 VCVCXSPOZXMIFE-UHFFFAOYSA-N 0.000 claims description 2
• SBGYWALMFBDTLU-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-9-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=CN=CC=3)=NC2=CN=C1NC1=CC=C(CN)C=C1 SBGYWALMFBDTLU-UHFFFAOYSA-N 0.000 claims description 2
• GTPLPLLKOJTSKV-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-5-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=CC=CN=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 GTPLPLLKOJTSKV-UHFFFAOYSA-N 0.000 claims description 2
• VILJIWHJLPKUBD-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-6-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C=C5C=CC=NC5=CC=4)=NC=C3N=2)C2CC2)=N1 VILJIWHJLPKUBD-UHFFFAOYSA-N 0.000 claims description 2
• OSJAUFLIZDQGAT-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]quinolin-8-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=NC=CC=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 OSJAUFLIZDQGAT-UHFFFAOYSA-N 0.000 claims description 2
• 125000003107 substituted aryl group Chemical group 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims description 2
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
• SBMBNAWOUOLYLZ-UHFFFAOYSA-N 1-n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]-3-n,3-n-dimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(NC=2N=C3N(C4CC4)C(C=4N=C(N)N=CC=4)=NC3=CN=2)=C1 SBMBNAWOUOLYLZ-UHFFFAOYSA-N 0.000 claims 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• DQZATBKGAJSHGC-UHFFFAOYSA-N n-[8-(2-aminopyrimidin-4-yl)-9-cyclopropylpurin-2-yl]isoquinolin-5-amine Chemical compound NC1=NC=CC(C=2N(C3=NC(NC=4C5=CC=NC=C5C=CC=4)=NC=C3N=2)C2CC2)=N1 DQZATBKGAJSHGC-UHFFFAOYSA-N 0.000 claims 1
• PBEUPWLAXCNWAE-UHFFFAOYSA-N tert-butyl n-[2-[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]ethyl]carbamate Chemical compound C1=CC(CCNC(=O)OC(C)(C)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 PBEUPWLAXCNWAE-UHFFFAOYSA-N 0.000 claims 1
• CKLOTJVEWYJNSA-UHFFFAOYSA-N tert-butyl n-[[4-[(9-cyclopropyl-8-pyridin-4-ylpurin-2-yl)amino]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1NC1=NC=C(N=C(C=2C=CN=CC=2)N2C3CC3)C2=N1 CKLOTJVEWYJNSA-UHFFFAOYSA-N 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 abstract description 6
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 257
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 65
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
• 239000000203 mixture Substances 0.000 description 38
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
• 239000000243 solution Substances 0.000 description 35
• 239000002904 solvent Substances 0.000 description 29
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
• 239000011541 reaction mixture Substances 0.000 description 26
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
• 239000000543 intermediate Substances 0.000 description 22
• 238000003786 synthesis reaction Methods 0.000 description 22
• 230000015572 biosynthetic process Effects 0.000 description 20
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
• 102000004877 Insulin Human genes 0.000 description 19
• 108090001061 Insulin Proteins 0.000 description 19
• 229940125396 insulin Drugs 0.000 description 19
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
• 210000004027 cell Anatomy 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 15
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 13
• 108091000080 Phosphotransferase Proteins 0.000 description 12
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
• SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 12
• 102000020233 phosphotransferase Human genes 0.000 description 12
• 108090000623 proteins and genes Proteins 0.000 description 12
• 101150041968 CDC13 gene Proteins 0.000 description 11
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 11
• 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 11
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 239000008103 glucose Substances 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 102000004169 proteins and genes Human genes 0.000 description 10
• 238000010992 reflux Methods 0.000 description 10
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 8
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 8
• 108091054455 MAP kinase family Proteins 0.000 description 8
• 102000043136 MAP kinase family Human genes 0.000 description 8
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 8
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000007995 HEPES buffer Substances 0.000 description 7
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
• 238000005481 NMR spectroscopy Methods 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 125000000753 cycloalkyl group Chemical group 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 235000019439 ethyl acetate Nutrition 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 230000014509 gene expression Effects 0.000 description 7
• 229910000027 potassium carbonate Inorganic materials 0.000 description 7
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
• 230000004190 glucose uptake Effects 0.000 description 6
• 239000004615 ingredient Substances 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 235000017557 sodium bicarbonate Nutrition 0.000 description 6
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 239000012453 solvate Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 5
• 239000007868 Raney catalyst Substances 0.000 description 5
• 229910000564 Raney nickel Inorganic materials 0.000 description 5
• 230000029936 alkylation Effects 0.000 description 5
• 238000005804 alkylation reaction Methods 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 125000004432 carbon atom Chemical group C* 0.000 description 5
• 238000003818 flash chromatography Methods 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
• 239000001301 oxygen Substances 0.000 description 5
• 239000011698 potassium fluoride Substances 0.000 description 5
• 150000003141 primary amines Chemical class 0.000 description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• HGTHYMOKILRDHL-UHFFFAOYSA-N 2-(methylamino)pyrimidine-4-carbaldehyde Chemical compound CNC1=NC=CC(C=O)=N1 HGTHYMOKILRDHL-UHFFFAOYSA-N 0.000 description 4
• GVTZVNRRGNBOJF-UHFFFAOYSA-N 4-(dimethoxymethyl)-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=CC(C(OC)OC)=N1 GVTZVNRRGNBOJF-UHFFFAOYSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• 206010022489 Insulin Resistance Diseases 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• 108091008606 PDGF receptors Proteins 0.000 description 4
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 108010004469 allophycocyanin Proteins 0.000 description 4
• 238000011861 anti-inflammatory therapy Methods 0.000 description 4
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000012267 brine Substances 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 102000015694 estrogen receptors Human genes 0.000 description 4
• 108010038795 estrogen receptors Proteins 0.000 description 4
• 230000009229 glucose formation Effects 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 201000001421 hyperglycemia Diseases 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 235000015320 potassium carbonate Nutrition 0.000 description 4
• 235000003270 potassium fluoride Nutrition 0.000 description 4
• JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• XVUGJKOKDLWVJJ-UHFFFAOYSA-N 2-(3-nitrophenyl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=CC([N+]([O-])=O)=C1 XVUGJKOKDLWVJJ-UHFFFAOYSA-N 0.000 description 3
• JFGUYYUCZSRMCF-UHFFFAOYSA-N 2-aminopyrimidine-4-carbaldehyde Chemical compound NC1=NC=CC(C=O)=N1 JFGUYYUCZSRMCF-UHFFFAOYSA-N 0.000 description 3
• NNWSQRLDWYRIRV-UHFFFAOYSA-N 2-chloro-n-cyclopropyl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1NC1CC1 NNWSQRLDWYRIRV-UHFFFAOYSA-N 0.000 description 3
• OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 208000032928 Dyslipidaemia Diseases 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 3
• 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 3
• 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 3
• 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 208000017170 Lipid metabolism disease Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 150000001448 anilines Chemical class 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 125000002619 bicyclic group Chemical group 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 235000011181 potassium carbonates Nutrition 0.000 description 3
• 238000012746 preparative thin layer chromatography Methods 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 238000011894 semi-preparative HPLC Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 239000003039 volatile agent Substances 0.000 description 3
• PAMJENUKCYUKLC-UHFFFAOYSA-N 1-(4-nitrobenzyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1CCCCC1 PAMJENUKCYUKLC-UHFFFAOYSA-N 0.000 description 2
• ZRDFCBNSANRTSD-UHFFFAOYSA-N 1-[2-(3-nitrophenyl)ethyl]piperidine Chemical compound [O-][N+](=O)C1=CC=CC(CCN2CCCCC2)=C1 ZRDFCBNSANRTSD-UHFFFAOYSA-N 0.000 description 2
• CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
• OQGFAPKRSPWPHR-UHFFFAOYSA-N 2-chloro-4-n-ethylpyrimidine-4,5-diamine Chemical compound CCNC1=NC(Cl)=NC=C1N OQGFAPKRSPWPHR-UHFFFAOYSA-N 0.000 description 2
• JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 description 2
• YIXRYDFFJSCVSP-UHFFFAOYSA-N 2-chloro-9-ethyl-8-pyridin-4-ylpurine Chemical compound N=1C2=CN=C(Cl)N=C2N(CC)C=1C1=CC=NC=C1 YIXRYDFFJSCVSP-UHFFFAOYSA-N 0.000 description 2
• MUAUTBNKPSNTFM-UHFFFAOYSA-N 2-phenylethyl carbamate Chemical compound NC(=O)OCCC1=CC=CC=C1 MUAUTBNKPSNTFM-UHFFFAOYSA-N 0.000 description 2
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• OQINWXZQCAIVNK-UHFFFAOYSA-N 4-(dimethoxymethyl)pyrimidin-2-amine Chemical compound COC(OC)C1=CC=NC(N)=N1 OQINWXZQCAIVNK-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 150000001350 alkyl halides Chemical class 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 238000006254 arylation reaction Methods 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 230000006583 body weight regulation Effects 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 239000000460 chlorine Chemical group 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 230000014101 glucose homeostasis Effects 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 150000005147 halomethylbenzenes Chemical class 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• 230000003914 insulin secretion Effects 0.000 description 2
• 230000004155 insulin signaling pathway Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229910052740 iodine Chemical group 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 238000000021 kinase assay Methods 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• CRBKFFVPLITHLR-UHFFFAOYSA-N n-[(4-nitrophenyl)methyl]ethanamine Chemical compound CCNCC1=CC=C([N+]([O-])=O)C=C1 CRBKFFVPLITHLR-UHFFFAOYSA-N 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 150000003138 primary alcohols Chemical class 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 2
• CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical class O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 2
• OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical compound O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 2
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• UDAWCYHLAQVQQB-UHFFFAOYSA-N tert-butyl n-ethyl-n-[(4-nitrophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CC)CC1=CC=C([N+]([O-])=O)C=C1 UDAWCYHLAQVQQB-UHFFFAOYSA-N 0.000 description 2
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
• 230000035924 thermogenesis Effects 0.000 description 2
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
• 239000012224 working solution Substances 0.000 description 2
• SMIXZZMSWYOQPW-UHFFFAOYSA-N (4-nitrophenyl)methylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=C([N+]([O-])=O)C=C1 SMIXZZMSWYOQPW-UHFFFAOYSA-N 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• MHYPLWZTFXKBEA-UHFFFAOYSA-N 2-chloro-n-ethyl-5-nitropyrimidin-4-amine Chemical compound CCNC1=NC(Cl)=NC=C1[N+]([O-])=O MHYPLWZTFXKBEA-UHFFFAOYSA-N 0.000 description 1
• HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 1
• 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• AEFCUBQBTTVKDN-UHFFFAOYSA-N 3-(2-piperidin-1-ylethyl)aniline Chemical compound NC1=CC=CC(CCN2CCCCC2)=C1 AEFCUBQBTTVKDN-UHFFFAOYSA-N 0.000 description 1
• 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
• ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
• ZHFFNLQQANCJEQ-UHFFFAOYSA-N 4-(2-morpholin-4-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1CCOCC1 ZHFFNLQQANCJEQ-UHFFFAOYSA-N 0.000 description 1
• DRYFDUUAYSVNSN-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCCCC1 DRYFDUUAYSVNSN-UHFFFAOYSA-N 0.000 description 1
• ANYJDIFHIHUTPB-UHFFFAOYSA-N 4-[9-ethyl-2-(4-fluorophenoxy)purin-8-yl]pyrimidin-2-amine Chemical compound N1=C2N(CC)C(C=3N=C(N)N=CC=3)=NC2=CN=C1OC1=CC=C(F)C=C1 ANYJDIFHIHUTPB-UHFFFAOYSA-N 0.000 description 1
• LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
• RYMQBWJQKNOBFR-UHFFFAOYSA-N 4-n-cyclopropyl-2-n-(2-thiophen-2-ylethyl)pyrimidine-2,4,5-triamine Chemical compound N1=C(NC2CC2)C(N)=CN=C1NCCC1=CC=CS1 RYMQBWJQKNOBFR-UHFFFAOYSA-N 0.000 description 1
• 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• LKZISXNNURITGC-UHFFFAOYSA-N 8-(2-chloropyridin-4-yl)-n-(4-fluorophenyl)-9-methylpurin-2-amine Chemical compound N1=C2N(C)C(C=3C=C(Cl)N=CC=3)=NC2=CN=C1NC1=CC=C(F)C=C1 LKZISXNNURITGC-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• FHAZARBWQZYJSD-UHFFFAOYSA-N 9-(4-methylphenyl)purin-2-amine Chemical compound C1=CC(C)=CC=C1N1C2=NC(N)=NC=C2N=C1 FHAZARBWQZYJSD-UHFFFAOYSA-N 0.000 description 1
• ZYSXILVXKJTJKB-UHFFFAOYSA-N 9-[(2,4-dimethoxyphenyl)methyl]-n-(4-fluorophenyl)-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC(OC)=CC=C1CN1C2=NC(NC=3C=CC(F)=CC=3)=NC=C2N=C1C1=CC=NC=C1 ZYSXILVXKJTJKB-UHFFFAOYSA-N 0.000 description 1
• SYXKZMPXYKAWIZ-UHFFFAOYSA-N 9-cyclopropyl-n-(3-methoxyphenyl)-n-methyl-8-pyridin-4-ylpurin-2-amine Chemical compound COC1=CC=CC(N(C)C=2N=C3N(C4CC4)C(C=4C=CN=CC=4)=NC3=CN=2)=C1 SYXKZMPXYKAWIZ-UHFFFAOYSA-N 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102000003910 Cyclin D Human genes 0.000 description 1
• 108090000259 Cyclin D Proteins 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• 239000001692 EU approved anti-caking agent Substances 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 102000020897 Formins Human genes 0.000 description 1
• 108091022623 Formins Proteins 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
• 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 208000031641 Ideal Body Weight Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
• GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
• UQPMANVRZYYQMD-UHFFFAOYSA-N N3-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C=12C(N)=NC=NC2=NNC=1NC1=CC=C(F)C=C1 UQPMANVRZYYQMD-UHFFFAOYSA-N 0.000 description 1
• 229910020700 Na3VO4 Inorganic materials 0.000 description 1
• 238000010934 O-alkylation reaction Methods 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 150000005018 aminopurines Chemical class 0.000 description 1
• 239000012296 anti-solvent Substances 0.000 description 1
• 239000000063 antileukemic agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000005518 carboxamido group Chemical group 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000007711 cytoplasmic localization Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 238000006264 debenzylation reaction Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
• XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 125000005553 heteroaryloxy group Chemical group 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 102000057747 human MKNK1 Human genes 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000006362 insulin response pathway Effects 0.000 description 1
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Chemical group 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000011565 manganese chloride Substances 0.000 description 1
• 229940099607 manganese chloride Drugs 0.000 description 1
• 235000002867 manganese chloride Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 238000003328 mesylation reaction Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• QYQYMVAVTKTFEK-UHFFFAOYSA-N n-[(4-aminophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(N)C=C1 QYQYMVAVTKTFEK-UHFFFAOYSA-N 0.000 description 1
• ZMQPYUAJBGXGCB-UHFFFAOYSA-N n-[(4-nitrophenyl)methyl]acetamide Chemical compound CC(=O)NCC1=CC=C([N+]([O-])=O)C=C1 ZMQPYUAJBGXGCB-UHFFFAOYSA-N 0.000 description 1
• 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• CSNFMBGHUOSBFU-UHFFFAOYSA-N pyrimidine-2,4,5-triamine Chemical compound NC1=NC=C(N)C(N)=N1 CSNFMBGHUOSBFU-UHFFFAOYSA-N 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000009703 regulation of cell differentiation Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000452 restraining effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
• CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• YRQMBQUMJFVZLF-UHFFFAOYSA-N tert-butyl n-(4-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(O)C=C1 YRQMBQUMJFVZLF-UHFFFAOYSA-N 0.000 description 1
• NCHPEYULQVABAW-UHFFFAOYSA-N tert-butyl n-[4-(2-morpholin-4-ylethoxy)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCN1CCOCC1 NCHPEYULQVABAW-UHFFFAOYSA-N 0.000 description 1
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1